AIM Vaccine Co., Ltd. (HKG:6660)

AIM Vaccine Revenue

AIM Vaccine had revenue of 350.63M CNY in the half year ending June 30, 2026, a decrease of -34.73%. This brings the company's total for the last twelve months to 1.00B, down -20.66% year-over-year. In the year 2025, AIM Vaccine had annual revenue of 1.17B, down -9.29%. That makes AIM Vaccine the 19,757th largest company in the world by revenue and 1,152nd in Hong Kong.

• Revenue (ttm): 1.00B CNY
• Revenue Growth: -20.66%
• P/S Ratio: 1.63
• Revenue / Employee: 740.32K CNY
• Employees: 1,353
• Market Cap: 1.82B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• Chinese Mainland 1.17B 100.0%
• Other Countries/Regions 375.00K 0.0%

Fiscal year ended Dec 31, 2025 See the full AIM Vaccine breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.17B	-119.36M	-9.29%
Dec 31, 2024	1.29B	97.56M	8.22%
Dec 31, 2023	1.19B	-76.61M	-6.06%
Dec 31, 2022	1.26B	-306.06M	-19.49%
Dec 31, 2021	1.57B	-67.84M	-4.14%

Data Source: S&P Global Market Intelligence Last updated: Aug 23, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 3, 2026

Data Sources Report a data error